Reducing Recurrent Preterm Birth: Appropriate Use of 17 Alpha Hydroxyprogesterone Caproate

Completing this online activity consists of five steps:

1. Read all information below
2. View the presentation
3. Take the posttest
4. Complete the registration and evaluation form
5. Fill out and print your receipt of hours completed

Release Date: October 15, 2008
Valid for credit through: October 14, 2009

Jointly Sponsored by University of Minnesota and March of Dimes, Minnesota Chapter.

Credits Available:
Up to 0.75 AMA PRA Category 1 CME credits

The leading cause of death and disability in the first month of life is premature delivery/low birth weight. While a number of interventions have been studied to prevent preterm birth, only 17P (17-alpha hydroxyprogesterone caproate) has been demonstrated as effective in a randomized controlled trial. This course summarizes risk factors for preterm birth, illustrates indications, use, administration and recommended dose of 17P, and reviews clinical trials concerning 17P. This activity also includes a demonstration of the Z-track injection.

Step One: READ ALL INFORMATION BELOW

Target Audience

Physicians in Obstetrics and Gynecology, Maternal-Fetal Medicine, and Family Medicine, as well as Physician Assistants, Nurse Practitioners, Midwives, and Nurses

Educational Objectives

After reading this article, you should be able to:

• Discuss the prevalence of preterm birthrates in Minnesota as well as their risk factors
• Explain the role of progesterone in pregnancy
• Discuss which gravidas would benefit most from the administration of 17 Alpha- hydroxyprogesterone to prevent preterm labor
• Discuss which gravidas would not benefit from the administration of 17 Alpha-hydroxyprogesterone to prevent preterm birth
• Recognize the proper technique for effectively administering an injection of 17 Alpha-hydroxyprogesterone

Estimated Time to Complete

45 minutes

Method of Participation

There are no fees to participate and receive CME credit for this activity. Participants must read the objectives and faculty disclosures, study the educational activity, complete the posttest by recording the best answer, register, and complete the evaluation. A statement of hours will then be issued on this Web site.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Minnesota and the March of Dimes-Minnesota.  The University of Minnesota is accredited by the ACCME to provide continuing medical education for physicians. 

The University of Minnesota designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credits™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, nurses, and other health care professionals who participate in this CME activity may submit their Statements of Attendance to their appropriate accrediting organizations or state boards for consideration of credit. The participant is responsible for determining whether this activity meets the requirements for acceptable continuing education.

Disclosure Statements

Course Director

Jessica Pike Swartout, MD
Fellow
Department of Obstetrics, Gynecology, and Women's Health
University of Minnesota Medical Center-Fairview
Division of Maternal Fetal Medicine
Disclosure: Ms. Pike Swartout has indicated no financial relationships to disclose.

Speakers

Kirk D. Ramin, MD
Associate Professor
University of Minnesota Medical Center-Fairview
Department of Obstetrics, Gynecology, and Women's Health
Division of Maternal Fetal Medicine
Disclosure: Dr. Ramin is a consultant for Enteromedics and Medtronic. He will discuss off label use and/or investigational use: most medications are not FDA approved for pregnancy.

Denise Turk, RN
Maternal Fetal Medicine Center-Fairview
Disclosure: Ms. Turk has indicated no financial relationships to disclose. She will discuss off label use and/or investigational use: most medications are not FDA approved for pregnancy.

Disclosure Policy

It is the policy of the University of Minnesota Office of Continuing Medical Education to ensure balance, independence, objectivity and scientific rigor in all of its sponsored educational activities.  All participating speakers, course directors, and planning committee members are required to disclose to the program audience any financial relationships related to the subject matter of this program Relationships of spouse/partner with proprietary entities producing health care goods or services should be disclosed if they are of a nature that may influence the objectivity of the individual in a position to control the content of the CME activity.  Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest.  Specific disclosure information for each speaker, course director, and planning committee member will be shared with the audience prior to the speaker’s presentation.

Commercial Support Information

Support for this program is provided by an unrestricted educational grant from March of Dimes-Minnesota.

Feedback

For feedback or questions, or for technical concerns, contact us at 612-626-7600 or cme@umn.edu.

Privacy Statement / Sharing of Private Data

View the University of Minnesota Online Privacy Statement: http://www.privacy.umn.edu/

Sharing of Private Data:

When you register for a Continuing Medical Education ("CME") or a Continuing Education ("CE") activity through our Web site, we collect certain personally identifiable information from you such as your name, email address and mailing address.

In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:

1. We are accredited by the Accreditation Council for Continuing Medical Education ("ACCME") to provide continuing medical education for physicians. As an ACCME accredited entity, we are required to periodically submit aggregated data about CME participants and the CME activities we certify. We also provide personally identifiable information to other accredited CME/CE providers who certify CME/CE activities posted on our Web sites, as required by the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from us for up to six (6) years.

2. Commercial supporters of CME/CE activities on our Web site will receive only aggregated data about CME/CE activities that are relevant to their interests and/or the courses they support.

3. Our Editorial and Customer Support Staff will have internal access to files containing personally identifiable information, including evaluation forms and aggregated CME /CE participant information. These files can be accessed in order to respond to your questions or comments. Our staff may also use personally identifiable information, including registration information and evaluation data, in assessing educational needs and planning marketing activities.

We do not share your information with any third party.

Step Two: VIEW THE PRESENTATION